

32. (New) A complex comprising the analog of claim 28 bound to an antibody to which the immunogen binds specifically.

33. (New) A method of identifying a polypeptide analog of a T cell-dependent immunogen comprising the steps of:

(a) screening a panel or library of candidate polypeptides for the presence of one or more B cell epitope(s) that specifically binds to antibodies to which the immunogen binds specifically;

(b) screening said candidate polypeptides identified in step (a) for candidate polypeptides lacking T cell epitope(s); and

(c) selecting a polypeptide analog from said candidate polypeptides that bind to the antibodies of step (a), but that do not contain T cell epitope(s) as determined by step (b).

34. (New) A method of making a polypeptide analog of a T cell-dependent immunogen comprising the step of removing T cell epitope(s) from a polypeptide comprising an epitope that binds specifically to antibodies to which the immunogen binds specifically.

35. (New) The method of claim 34, wherein the T cell epitope(s) is removed by altering the T cell epitope(s).

36. (New) The method of claim 34, wherein the T cell epitope(s) is removed by deleting the T cell epitope(s).

37. (New) A method of making a polypeptide analog of a T cell-dependent immunogen comprising the steps of

(a) synthesizing the polypeptide analog, whereby the polypeptide analog comprises an epitope that binds specifically to antibodies to which the immunogen binds specifically, wherein the analog lacks T cell epitopes capable of activating T cells in an individual; and

(b) purifying the analog.

38. (New) A purified analog of a T cell-dependent immunogen, said analog comprising an epitope that binds specifically to an antibody to which the immunogen binds specifically, wherein the analog has a T cell stimulation index below about 2-3, and wherein the analog is a polypeptide.

39. (New) The analog of claim 38, wherein the analog has a T cell stimulation index below about 1-2.

40. (New) The analog of claim 38, further comprising a functional group for coupling to a carrier.

41. (New) The analog of claim 38, wherein the T cell-dependent immunogen is implicated in an antibody-mediated pathology and the individual has the antibody-mediated pathology.

42. (New) A composition comprising the analog of claim 38 and a buffer.

43. (New) A complex comprising the analog of claim 38 bound to an antibody to which the immunogen binds specifically.